Vol. 22/No. 01 | OncologyLive

Adult Nonmalignant Hematology Is an Endangered Field That Merits Protection

January 21, 2021

Partner Perspective

The scope of adult nonmalignant hematology can be broad and includes thrombotic and hemorrhagic disorders, transfusion medicine, hemoglobin disorders including sickle cell disease and thalassemia, anemia, thrombocytopenia, leukocytosis, leukopenia, and disorders of iron metabolism.

HER2-Directed Antibody-Drug Conjugates May Carve Out a Place in NSCLC Landscape

January 21, 2021

The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.

PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20, 2021

From the Editor

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 08, 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 06, 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.